Eupraxia Pharmaceuticals is trading 9.9% down at $7.01, with no clear company-specific announcement identified for October 8.
- The latest surfaced company news was its September 30 report of 52-week trial data; a broker page listed no October 8 headlines.
- U.S. futures and global markets were under pressure amid rising Treasury yields and oil-related inflation concerns, but sources do not establish these factors as the direct cause of the stock’s move.